Dabrafenib (Dabrafenib)
Overview of Dabrafenib
Dabrafenib mesylate is a kinase inhibitor. The chemical name for dabrafenib mesylate is N-{3- [5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6- difluorobenzene sulfonamide, methanesulfonate salt. it is used for the treatment of patients with unresectable or metastatic melanoma with braf V600E mutation.
Indication of Dabrafenib
Dabrafenib is primarily indicated in conditions like Metastatic melanoma, Metastatic melanoma.
Contraindication of Dabrafenib
No data regarding the contra indications of Dabrafenib is available.
Side Effects of Dabrafenib
The symptomatic adverse reactions produced by Dabrafenib are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Fatigue, Nausea, Vomiting, Alopecia, Myalgia, Constipation, Chills, Cough, Arthralgia, Pyrexia, Alopecia, Rash, hyperkeratosis, papilloma, palmae plantar erythrodysesthesia syndrome, pyrexia, night sweats, myalgia.
Precautions of Dabrafenib
new malignancies (cutaneous and non cutaneous), tumor promotion in BRAF wild-type melanoma,Hemorrhage, venous Thromboembolism, cardiomyopathy, ocular toxicities, serious febrile reactions, serious skin toxicity, hyperglycemia, glucose -6 -phosphate dehydrogenase deficiency, embryofetal toxicity,